EMA greenlights BioNtech’s COVID-19 vaccine
Following a rapid FDA approval, the European drug authority EMA has recommended to conditionally approve BioNTechs mRNA vaccine BNT162b2 in the EU.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1425 entries already.
Entries by Thomas Gabrielczyk
European Circular Bioeconomy Fund growing
/in News/by Thomas GabrielczykOnly two and a half months after its launch, the EU bioecocomy venture capital fund ECBF has doubled the volume of its first closing.
Novo Holdings creates Hemab
/in News/by Thomas GabrielczykDanish Novo Holdings has founded Hemab ApS that is focussed on fighting orphan bleeding disorders by bi-specific antibodies.
Biotech companies launch Biotech Austria
/in News/by Thomas GabrielczykAustria has needed a biotech association for a long time. In just two months, entrepreneurs have launched Biotech Austria.
How microplastic particles get into the body
/in News/by Thomas GabrielczykWeathered microplastic particles may pose a greater risk than pristine ones, suggests a study of German researchers on mouse cells.
Centogene and Anylam launch clinical programme
/in News/by Thomas GabrielczykDiagnostics developer Centogene NV and Alnylam Pharmaceuticals launched a clinical programme aimed at improving ATTRv diagnosis.
Avantium NV bags money for demo plant
/in News/by Thomas GabrielczykGreen chemistry company Avantium NV has secured a 7.5m funding from the National Programme Groningen to support the construction of a 5 kilotonnes FDCA plant.
How stress brings cancer to life again
/in News/by Thomas GabrielczykStress hormones such as cortisol or norephidrine can reawaken dormant tumour cells, a research team led by AstraZeneca has found out.
Swiss Noema Pharma raises CHF54m in Series A financing
/in News/by Thomas GabrielczykNoema Pharma AG kicks off with CHF54m and licenced drug candidates from Roche AG.
Germany first EU country to launch COVID-19 therapy offensive?
/in News/by Thomas GabrielczykAfter months of lobbying by the BIOM biotech cluster, Bavaria is launching a 50m initiative to push the best and fastest COVID-19 therapies.